SCHEMBL499205

SCHEMBL499205

N[C@@H](Cc1cccc(CP(=O)(O)O)c1)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.66
MEN1 O00255 1/20 0.61
ALOX15 P16050 1/20 0.61
CYP2C19 P33261 1/20 0.61
KMT2A Q03164 1/20 0.61
HSD17B10 Q99714 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
SLC7A5 Q01650 3/20 0.59
ALPI P09923 1/20 0.59
PKM P14618 1/20 0.59
PTGS1 P23219 1/20 0.59
XIAP P98170 1/20 0.59
GRIA2 P42262 1/20 0.56
NOS3 P29474 1/20 0.55
NOS1 P29475 1/20 0.55
NOS2 P35228 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6021374 1.00 MAPK1 (0.66) MAPK1MEN1ALOX15CYP2C19KMT2A
Hydrochloric Acid SCHEMBL9152009 0.98 MAPK1 (0.64) MAPK1MEN1ALOX15CYP2C19KMT2A
Hydrochloric Acid SCHEMBL9151999 0.98 MAPK1 (0.64) MAPK1MEN1ALOX15CYP2C19KMT2A
SCHEMBL14028487 0.91 SLC7A5 (0.59) MAPK1SLC7A5ALPIPKMPTGS1
Tetrahydrofuran SCHEMBL9164887 0.89 MAPK1 (0.56) MAPK1MEN1ALOX15CYP2C19KMT2A
SCHEMBL2314258 0.87 SLC7A5 (0.77) ALOX15HSD17B10TDP1SLC7A5ALPI
SCHEMBL9150578 0.85 SLC7A5 (0.58) MAPK1SLC7A5ALPIPKMPTGS1
SCHEMBL9150583 0.85 SLC7A5 (0.58) MAPK1SLC7A5ALPIPKMPTGS1
Hydrochloric Acid SCHEMBL9157628 0.84 SLC7A5 (0.57) MAPK1SLC7A5ALPIPKMPTGS1
Hydrochloric Acid SCHEMBL9155868 0.84 SLC7A5 (0.57) MAPK1SLC7A5ALPIPKMPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724049-A1 MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF Catalent Ontario Limited (CA) 2026-04-15 EP claimed
WO-2024254056-A1 MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF CATALENT ONTARIO LIMITED (CA) 2024-12-12 WO claimed
CN-102143961-B Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity NEURAXON INC 2014-11-05 CN claimed
US-8586620-B2 Substituted indole compounds having NOS inhibitory activity NEURAXON, INC. (CA) 2013-11-19 US claimed
JP-2011526251-A 2011-10-06 JP claimed
US-20110212947-A1 SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NEURAXON INC. (CA) 2011-09-01 US claimed
CN-102143961-A Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity NEURAXON INC 2011-08-03 CN claimed
EP-2310386-A1 BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY Neuraxon Inc. (CA) 2011-04-20 EP claimed
EP-1883451-B9 SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NEURAXON INC (CA) 2011-02-09 EP claimed
EP-1883451-B1 SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NEURAXON INC (CA) 2010-11-24 EP claimed
EP-1649857-A2 New use of glutamate antagonists for the treatment of cancer Ikonomidou, Hrissanthi (DE) 2006-04-26 EP claimed
US-20050054650-A1 Use of glutamate antagonists for the treatment of cancer IKONOMIDOU HRISSANTHI (DE) 2005-03-10 US claimed
WO-2004105699-A2 COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE PHARMACIA CORPORATION (US) 2004-12-09 WO claimed
WO-2004039371-A2 COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF NEUROPATHIC PAIN PHARMACIA CORPORATION (US) 2004-05-13 WO claimed
US-20040082543-A1 Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain PHARMACIA CORPORATION 2004-04-29 US claimed
EP-1002535-A1 New use of glutamate antagonists for the treatment of cancer Ikonomidou, Hrissanthi (DE) 2000-05-24 EP claimed
US-5695751-A ADMINISTERING L-AMINO ACID OXIDASE TO REDUCE PLASMA LEVEL OF LARGE AMINO ACIDS TO ALLOW INCREASED TRANSPORT OF LARGE AMINO ACID DRUGS ACROSS BLOOD BRAIN BARRIER CORNELL RESEARCH FOUNDATION, INC. (US) 1997-12-09 US claimed
EP-0318935-B1 Substituted alpha-amino acids having pharmaceutical activity WARNER LAMBERT CO (US) 1995-02-01 EP claimed
US-5175153-A Antiischemic agents or antiepileptic agents WARNER-LAMBERT COMPANY (US) 1992-12-29 US claimed
EP-0318935-A2 Substituted alpha-amino acids having pharmaceutical activity WARNER-LAMBERT COMPANY (US) 1989-06-07 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212947-A1 SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NOS2, NOS1, NOS3 MAPK1 1748/4885MEN1 3810/4885ALOX15 420/4885
US-20040082543-A1 Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain GRIN2A, GRIN2B, GRIN3A MAPK1 1764/4885MEN1 4256/4885ALOX15 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.